Development of a model for prediction of coronary atherosclerotic regression: Evaluation of high-density lipoprotein cho esterol level and peripheral blood monocyte count

Heart and Vessels

Volumn 27, Issue 2, 2012, Pages 143-150

  Tani, Shigemasa ^a,b   Matsumoto, Michiaki ^a,b   Anazawa, Takeo ^a,b   Kawamata, Hirofumi ^a,b   Furuya, Shingo ^a,b   Takahashi, Hiroshi ^a,b   Iida, Kiyoshi ^a,b   Washio, Takehiko ^a,b   Kumabe, Narimichi ^a,b   Kobori, Masashi ^a,b   Nagao, Ken ^a,b   Hirayama, Atsushi ^b  

^a NIHON UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; High density lipoprotein cholesterol; Intravascular ultrasound; Monocyte count; Statin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYALGIA; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; UNSPECIFIED SIDE EFFECT;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; PRAVASTATIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84862980158     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-011-0130-8     Document Type: Article

References (27)

1. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126
2. Shah PK, Kaul S, Nilsson J, Cercek B (1999) Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104: 2376-2383 (Pubitemid 33049524)
3. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E (2005) Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol\70 mg/dl and C-reactive protein\2 mg/ l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45: 1644-1648 (Pubitemid 40704500)
4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714 (Pubitemid 8110784)
5. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H, Iida K, Matsumoto M, Washio T, Kumabe N, Hirayama A (2009) Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol 104: 464-469
6. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H, Iida K, Matsumoto M, Washio T, Kumabe N, Hirayama A (2010) Coronary plaque regression and lifestyle modification in patients treated with pravastatin. Circ J 74: 954-961
7. Ishikawa K, Tani S, Watanabe I, Matsumoto M, Furukawa K, Nomoto K, Nomoto K, Kushiro T, Nagao K, Kanmatsuse K (2003) Effect of pravastatin on coronary plaque volume. Am J Cardiol 92: 975-977 (Pubitemid 37214814)
8. Chapman CM, Beilby JP, McQuillan BM, Thompson PL, Hung J (2004) Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 35: 1619-1624 (Pubitemid 38823636)
9. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, Hafner G, Treude R, Othman H, Hofmann KP, Meyer J, AtheroGene Investigators (2002) Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89: 901-908 (Pubitemid 34310284)
10. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE (2007) Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297: 499-508 (Pubitemid 46220805)
11. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, Investigators COSMOS (2009) Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 73: 2110-2117
12. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, Sato Y, Nagao K, Kanmatsuse K, Kushiro T, Surugadai Atherosclerosis Regression Investigators (2005) Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by threedimensional intravascular ultrasound. Am J Cardiol 96: 1089-1094
13. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H, Iida K, Matsumoto M, Washio T, Kamabe N, Hirayama A (2010) Relation of change in the apolipoprotein B/apolipoprotein A-I ratio to coronary plaque regression following Pravastatin treatment in patients with coronary artery disease. Am J Cardiol 105: 144-148
14. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H (2004) Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 110: 1061-1068 (Pubitemid 39319003)
15. Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Nanto S, Takazawa K, Kodama K (2009) Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ J 73: 718-725
16. Jia X, Wei M, Fu X, Gu X, Fan W, Zhang J, Xue L (2009) Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients. Heart Vessels 24: 340-346
17. Suzuki T, Nozawa T, Fujii N, Sobajima M, Ohori T, Shida T, Matsuki A, Kameyama T, Inoue H (2010) Plaque regression in one artery is not necessarily associated with parallel changes in other vascular beds. Heart Vessels. doi: 10.1007/s00380-010-0049-5
18. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, UnoK, Tuzcu EM, Nissen SE (2010) Intravascular ultrasound-derivedmeasures of coronary atherosclerotic plaque burden and clinicaloutcome. J Am Coll Cardiol 55: 2399-2407
19. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators (2009) Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study). J Am Coll Cardiol 54 (4): 293-302
20. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P, Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29-38
21. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, ASTEROID Tuzcu EM Investigators (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295: 1556-1565
22. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, MEGA Study Group (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368: 1155-1163 (Pubitemid 44444932)
23. Matsuzawa Y, Kita T, Shepherd J, Gotto AM Jr, Nakamura H, Sacks FM, Oikawa S, Sasaki J (2007) A trilogy of primary prevention statin trials. Panel discussion. Atheroscler Suppl 8: 19-24
24. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A (1994) Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90: 583-612
25. Ueshima H (2007) Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. J Atheroscler Thromb 14: 278-286
26. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73: 554-565 (Pubitemid 37249126)
27. Tirona RG (2005) Ethnic differences in statin disposition. Clin Pharmacol Ther 78: 311-316 (Pubitemid 41393665)